Einzeltreffer — DigiBib

This study investigated the effects of sinusoidal ELF-MF (1 mT; 50 Hz) on the apoptosis induced by four different compounds, namely vinblastine, etoposide, quercetin, and resveratrol, in human K562 chronic myeloid leukemia cells. The exposure to ELF-MF did not affect growth and viability of untreated K562 cells and did not influence the anti-proliferative effects of resveratrol, vinblastine, and etoposide. On the contrary, in quercetin-treated cells, exposure to ELF-MF significantly reduced the percentage of apoptotic cells and the caspase-3 activity and modified the cell cycle profile especially after 48 h of exposure. In addition, the simultaneous treatments for 24 h with quercetin plus ELF-MF increased Bcl-2 protein expression and prevented quercetin-induced downregulation of Mcl-1 and Bcl-xL. Finally, an increase of HSP70 expression was also observed after prolonged ELF-MF treatment. The ELF-MF-dependent modulation of the expression of anti-apoptotic Bcl-2 family and Hsp70 proteins could act as a pro-survival mechanism in K562 cells.

Titel:	ELF-MF attenuates quercetin-induced apoptosis in K562 cells through modulating the expression of Bcl-2 family proteins.
Autor/in / Beteiligte Person:	Brisdelli, F ; Bennato, F ; Bozzi, A ; Cinque, B ; Mancini, F ; Iorio, R
Link:	Full Text Finder (Volltext)
Zeitschrift:	Molecular and cellular biochemistry, Jg. 397 (2014-12-01), Heft 1-2, S. 33-43
Veröffentlichung:	New York : Springer ; <i>Original Publication</i>: The Hague, Dr. W. Junk B. V. Publishers., 2014
Medientyp:	academicJournal
ISSN:	1573-4919 (electronic)
DOI:	10.1007/s11010-014-2169-1
Schlagwort:	Caspase 3 metabolism Down-Regulation drug effects Humans K562 Cells Antioxidants pharmacology Apoptosis drug effects Gene Expression Regulation, Leukemic drug effects Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy Magnetic Fields Proto-Oncogene Proteins c-bcl-2 biosynthesis Quercetin pharmacology bcl-X Protein biosynthesis
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Mol Cell Biochem] 2014 Dec; Vol. 397 (1-2), pp. 33-43. <i>Date of Electronic Publication: </i>2014 Aug 02. MeSH Terms: Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy ; Magnetic Fields* ; Antioxidants / pharmacology ; Apoptosis / drug effects ; Gene Expression Regulation, Leukemic / drug effects ; Proto-Oncogene Proteins c-bcl-2 / biosynthesis ; Quercetin / pharmacology ; bcl-X Protein / biosynthesis ; Caspase 3 / metabolism ; Down-Regulation / drug effects ; Humans ; K562 Cells References: Mol Cell Biochem. 2007 Feb;296(1-2):137-49. (PMID: 16969687) ; Curr Drug Metab. 2009 Jul;10(6):530-46. (PMID: 19702538) ; Biochem Biophys Res Commun. 2001 Sep 7;286(5):953-7. (PMID: 11527392) ; J Cell Physiol. 2009 May;219(2):334-43. (PMID: 19115234) ; Bioelectromagnetics. 1998;19(2):85-91. (PMID: 9492164) ; J Nutr Biochem. 2005 Mar;16(3):155-62. (PMID: 15741050) ; Bioelectromagnetics. 2012 Dec;33(8):641-51. (PMID: 22535669) ; Radiat Environ Biophys. 2010 Nov;49(4):731-41. (PMID: 20582429) ; Acta Biol Hung. 2010 Jun;61(2):158-67. (PMID: 20519170) ; Biochem Biophys Res Commun. 2002 Mar 29;292(2):355-61. (PMID: 11906169) ; Altern Med Rev. 2011 Jun;16(2):172-94. (PMID: 21649459) ; Biochem Pharmacol. 2004 Nov 15;68(10):2019-30. (PMID: 15476673) ; Cancer Res. 1994 Sep 15;54(18):4952-7. (PMID: 8069862) ; FASEB J. 1999 Jan;13(1):95-102. (PMID: 9872934) ; Bioelectromagnetics. 1992;13(5):401-11. (PMID: 1445421) ; Cancer Chemother Pharmacol. 2005 Mar;55(3):251-62. (PMID: 15538571) ; Br J Dermatol. 2008 Jun;158(6):1189-96. (PMID: 18410412) ; Biochim Biophys Acta. 2005 Mar 22;1743(1-2):120-9. (PMID: 15777847) ; Environ Res. 2004 Feb;94(2):145-51. (PMID: 14757377) ; PLoS One. 2011 Mar 23;6(3):e18021. (PMID: 21448285) ; Bioelectromagnetics. 1993;14(3):247-55. (PMID: 8391817) ; J Cell Physiol. 2011 Nov;226(11):2901-7. (PMID: 21302292) ; Ann N Y Acad Sci. 2006 Dec;1090:59-68. (PMID: 17384247) ; J Biol Chem. 2005 Mar 18;280(11):10491-500. (PMID: 15637055) ; Chem Res Toxicol. 1992 Mar-Apr;5(2):227-31. (PMID: 1322737) ; Annu Rev Physiol. 2008;70:73-91. (PMID: 17680735) ; Mutat Res. 2010 Jan 5;683(1-2):74-83. (PMID: 19896957) ; Gen Physiol Biophys. 2012 Mar;31(1):1-10. (PMID: 22447825) ; Electromagn Biol Med. 2010 Aug;29(3):122-30. (PMID: 20707646) ; Blood. 2003 Nov 1;102(9):3179-85. (PMID: 12855558) ; Occup Environ Med. 2007 Aug;64(8):553-9. (PMID: 17525094) ; Methods Cell Biol. 1995;46:153-85. (PMID: 7541883) ; Eur J Pharmacol. 2010 Dec 15;649(1-3):84-91. (PMID: 20858478) ; J Physiol Pharmacol. 2005 Dec;56 Suppl 6:101-8. (PMID: 16340043) ; Int J Radiat Biol. 2013 Jul;89(7):548-61. (PMID: 23367877) ; Crit Rev Clin Lab Sci. 2006;43(1):1-67. (PMID: 16531274) ; J Cancer Res Clin Oncol. 2005 Nov;131(11):765-71. (PMID: 16049707) ; Cardiology. 2010;117(1):54-6. (PMID: 20924178) ; J Biomed Biotechnol. 2009;2009:834239. (PMID: 19672456) ; Int J Radiat Biol. 2005 Jan;81(1):1-11. (PMID: 15962758) ; J Cell Physiol. 2008 Apr;215(1):129-39. (PMID: 17941084) ; Biochem Biophys Res Commun. 2010 Oct 1;400(4):739-44. (PMID: 20816755) ; J Immunol Methods. 2002 Jul 1;265(1-2):97-110. (PMID: 12072181) ; Bioelectromagnetics. 2009 Feb;30(2):163-5. (PMID: 19051321) ; Biochem Pharmacol. 2005 May 15;69(10):1421-32. (PMID: 15857606) ; Bioelectromagnetics. 2011 Jan;32(1):15-27. (PMID: 20690107) Substance Nomenclature: 0 (Antioxidants) ; 0 (BCL2 protein, human) ; 0 (BCL2L1 protein, human) ; 0 (Proto-Oncogene Proteins c-bcl-2) ; 0 (bcl-X Protein) ; 9IKM0I5T1E (Quercetin) ; EC 3.4.22.- (CASP3 protein, human) ; EC 3.4.22.- (Caspase 3) Entry Date(s): Date Created: 20140803 Date Completed: 20150629 Latest Revision: 20211021 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

ELF-MF attenuates quercetin-induced apoptosis in K562 cells through modulating the expression of Bcl-2 family proteins.